Roche launches AI-enabled predictive CGM solution at landmark Dubai event
Roche Diagnostics Middle East has unveiled Accu-Chek SmartGuide, an AI-enabled continuous glucose monitoring (CGM) solution designed to transform diabetes management across the Middle East. The launch was marked by a landmark event held at The Obelisk in Dubai, bringing together senior government officials, healthcare leaders, and global experts.
The event featured keynote addresses by H.E. Dr. Hussain Abdul Rahman Al Rand, Assistant Undersecretary for the Public Health Sector; H.E. Arthur Mattli, Ambassador of Switzerland to the UAE and Bahrain; Guido Sander, General Manager of Roche Diagnostics Middle East; and Dr. Abdullah Mohammed Arabe, Director of Diabetes Centres, Diabetic Foot Centres, and the Osteoporosis Department at Saudi Arabia’s Ministry of Health.
In his keynote speech, Dr. Al Rand emphasised the UAE’s commitment to innovation-driven healthcare under the UAE Health Vision 2030, highlighting the role of evidence-based partnerships in improving population health outcomes and preventing chronic disease.
The launch programme explored how AI-enabled CGM technology is advancing personalised healthcare by enabling predictive, rather than reactive, diabetes management. Panel discussions examined the practical application of artificial intelligence in disease prediction and its growing role in modern healthcare systems, supported by insights from regional and international experts.
With more than 1.3 million adults living with diabetes in the UAE, Roche highlighted the potential impact of Accu-Chek SmartGuide in addressing one of the region’s most pressing public health challenges. Unmanaged diabetes is associated with serious complications, including cardiovascular disease, kidney failure, nerve damage, vision loss, lower-limb amputation, and mental health conditions.
Guido Sander said the new CGM solution represents a shift toward predictive, patient-centred care, empowering individuals to manage their condition proactively while providing healthcare professionals with deeper, data-driven insights to personalise treatment and improve outcomes.
Already available in Kuwait, Saudi Arabia, and Qatar, Accu-Chek SmartGuide uses artificial intelligence to forecast glucose levels over the next 30 minutes, two hours, and overnight. By anticipating glucose fluctuations, the system aims to reduce uncertainty, improve adherence to therapy, and lower the risk of hypoglycaemia and long-term complications.
The solution includes a wireless, water-resistant sensor worn on the back of the upper arm, which transmits glucose readings every five minutes to a mobile application. Using AI-trained algorithms and optional user inputs such as insulin doses and food intake, the app detects patterns and predicts future glucose levels, offering alerts and guidance to help users maintain glucose within target ranges.
Clinical studies have demonstrated high system accuracy, with a mean absolute relative difference (MARD) of 9.2 per cent and 99.8 per cent of measured glucose values falling within clinically acceptable ranges. Roche stated that all advanced predictive features exceeded performance benchmarks for accuracy, sensitivity, and specificity.
The Middle East launch reinforces Roche’s long-term commitment to advancing diabetes care through innovation, supporting patients in leading healthier lives while helping healthcare systems manage the growing burden of chronic disease.
